Comparing Sorafenib and Radiofrequency Ablation for Liver Cancer Treatment
Author Information
Author(s): Junxiao Wang, Rui Liu, Zhenyu Wen, Zejie Sang, Xiang Yang, Mingchao Ding, Hui Xie
Primary Institution: Fifth Medical Center of Chinese PLA General Hospital
Hypothesis
Is the combination of sorafenib with radiofrequency ablation more effective than radiofrequency ablation alone for treating early hepatocellular carcinoma?
Conclusion
Adding sorafenib to radiofrequency ablation did not improve overall survival compared to radiofrequency ablation alone, but the side effects of sorafenib were manageable.
Supporting Evidence
- The median overall survival was 35.0 months for RFA and 41.0 months for RFA+Sor.
- The recurrence-free survival rates at 1, 2, and 3 years were similar between the two groups.
- Skin rashes were the only significant adverse effect noted in the RFA+Sor group.
Takeaway
Doctors wanted to see if a medicine called sorafenib helps people with liver cancer when used with a treatment called radiofrequency ablation, but it didn't make them live longer than just using radiofrequency ablation alone.
Methodology
The study included 164 patients with early hepatocellular carcinoma, comparing those who received radiofrequency ablation alone to those who received it with sorafenib, measuring overall survival and recurrence-free survival.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study was retrospective, and confounding factors may have influenced the outcomes.
Participant Demographics
Patients were aged 18-75, with a majority being male and having hepatitis B virus infection as the main cause of HCC.
Statistical Information
P-Value
P=0.265
Confidence Interval
95% CI: 29.99, 40.01 for OS in RFA group; 95% CI: 34.28, 47.72 for OS in RFA+Sor group
Statistical Significance
P>0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website